ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.
ETFOptimize | HOME
Close Window
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics to Present at the 8th Annual IPF Summit

By: via Business Wire

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrotic diseases, chronic inflammatory diseases and diverse cancers, today announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8th Annual IPF Summit being held in Boston, MA on August 22, 2024.

Presentation Title: Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment

Session: Examining the Future Directions of the Pulmonary Fibrosis Landscape to Bring Better Drugs to Patients Faster

Date & Time: Thursday, August 22, 2024, at 3:45 PM ET

Panel Discussion Title: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates

Session: Looking Beyond Monotherapy & The Current Standard of Care to Combining Existing & Emerging Therapeutics for a Combination Approach

Date & Time: Thursday, August 22, 2024, at 10:00 AM ET

The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein that plays a central role in the pathogenesis of many fibrotic and inflammatory diseases. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter).

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.97
+2.76 (1.23%)
AAPL  268.81
+5.99 (2.28%)
AMD  259.67
+6.75 (2.67%)
BAC  53.02
+0.45 (0.86%)
GOOG  269.93
+9.42 (3.62%)
META  750.82
+12.46 (1.69%)
MSFT  531.52
+7.91 (1.51%)
NVDA  191.49
+5.23 (2.81%)
ORCL  281.40
-1.93 (-0.68%)
TSLA  452.42
+18.70 (4.31%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.


 
IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.